BACKGROUND: We have previously developed an oncolytic serotype 5 adenovirus (Ad5) with chromogranin-A (CgA) promoter-controlled E1A expression. Ad[CgA-E1A]. with the intention to treat neuroendocrine tumors. including carcinoids. https://poolsproductscanadas.shop/product-category/jandy-levolor-parts/